Rania Alem, Loubna Omri, Sihame Lkhoyaali, El Ghissassi Ibrahim, Boutayeb Saber, Mrabti Hind, Errihani Hassan
Journal: Medpeer Publisher
ISSN: 3066-2737
Volume: 2
Issue: 8
Date of Publication: 2025/08/27
Introduction:
Everolimus, an mTOR pathway inhibitor, is a recognized therapeutic option for several advanced solid cancers. Although its safety profile has been documented in clinical trials, it remains poorly studied in real- world settings, particularly in Morocco.
Objective:
Evaluate the clinical and biological tolerability of Everolimus in patients with metastatic cancer treated at the National Institute of Oncology (INO) in Rabat.
Methods:
This is a retrospective descriptive and analytical study conducted between January 2020 and October 2022. Twenty patients, mostly with hormone receptor-positive breast cancer, were treated with Everolimus as monotherapy or in combination with hormone therapy. Tolerance was assessed according to version 5.0 of the CTC-NCI criteria.
Results:
The average age of the patients was 53 years, with a predominance of women 16 patients (80%). Breast cancer accounted for 70% of indications (14 patients). The adverse effects reported were moderate, with hyperglycemia in 20% of cases (4 patients), requiring oral antidiabetic treatment, and grade 1 mucositis in 10% of cases (2 patients) . No serious infectious events were observed.
Conclusion:
Everolimus showed a good tolerance profile in our cohort, with manageable toxicities under close monitoring. These results confirm the feasibility of its use in real-world practice, while highlighting the importance of personalized follow-up. Larger studies, including pharmacogenetic evaluation, are needed to refine the therapeutic strategy in the Moroccan population.
mucositis, metastatic cancer, targeted therapy, tolerance, everolimus
Download PDF